HBM Holdings partners with Bristol Myers Squibb for antibody discovery

HBM Holdings Limited, also known as Harbour BioMed, announced a multi-year global strategic collaboration and license agreement with Bristol Myers Squibb, effective December 17, 2025. The partnership aims to accelerate the discovery and development of next-generation multi-specific antibodies.

Under the terms of the agreement, Harbour BioMed stands to receive total payments of $90 million, along with potential development and commercial milestones of up to $1,035 million. The agreement also includes tiered royalties should Bristol Myers Squibb choose to advance any of the potential programs.

The company cautioned shareholders and potential investors regarding the uncertainty of successfully developing or marketing product candidates, advising due care when dealing in its shares. The announcement was made by order of the board, signed by Dr. Jingsong Wang, chairman and executive director.